Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy
Roddy WalshiD, Francesco MazzarottoiD, Nicola WhiffiniD, Rachel J. BuchaniD, William Midwinter, Alicja Wilk, Nicholas LiiD, Leanne E. FelkiniD, Nathan IngoldiD, Risha GovindiD, Mian Ahmad, Erica MazaikaiD, Mona AlloubaiD, Xiaolei ZhangiD, Antonio de MarvaoiD, Sharlene M. DayiD, Euan Angus AshleyiD, Steven D. ColaniD, Michelle MichelsiD, Alexandre C. PereiraiD, Daniel Louis JacobyiD, Carolyn Yung HoiD, Kate L. ThomsoniD, Hugh C WatkinsiD, Paul J.R. BartoniD, , James S. WareiD
Abstract
BackgroundInternational guidelines for variant interpretation in Mendelian disease set stringent criteria to report a variant as (likely) pathogenic, prioritising control of false positive rate over test sensitivity and diagnostic yield. Genetic testing is also more likely informative in individuals with well-characterised variants from extensively studied European-ancestry populations. Inherited cardiomyopathies are relatively common Mendelian diseases that allow empirical calibration and assessment of this framework.\n\nResultsWe compared rare variants in large hypertrophic cardiomyopathy (HCM) cohorts to reference populations to identify variant classes with high prior likelihoods of pathogenicity, as defined by etiological fraction (EF). Analysis of variant distribution identified regions in which variants are significantly enriched in cases and variant location was a better discriminator of pathogenicity than generic computational functional prediction algorithms. Non-truncating variant classes with an EF[≥]0.95, and therefore clinically actionable, were identified in 5 established HCM genes. Applying this approach leads to an estimated 14-20% increase in cases with actionable HCM variants.\n\nConclusionsWhen found in a patient confirmed to have disease, novel variants in some genes and regions are empirically shown to have a sufficiently high probability of pathogenicity to support a \"likely pathogenic\" classification, even without additional segregation or functional data. This could increase the yield of high confidence actionable variants, consistent with the framework and recommendations of current guidelines. The techniques outlined offer a consistent, unbiased and equitable approach to variant interpretation for Mendelian disease genetic testing. We propose adaptations to ACMG/AMP guidelines to incorporate such evidence in a quantitative and transparent manner.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 120
- FWCI
- 10.81
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reclassification of Genetic Variants in Patients with Hypertrophic Cardiomyopathy from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Sophie Hespe, G. Powell, … Jodie Ingles·Heart Lung and CirculationPeer-reviewed·Jul 30, 2026
- Genetic, Clinical, and Sociodemographic Profile in Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort
Emerson de Santana Santos, Gabriel da Costa Kuhn, … Joselina Luzia Menezes Oliveira·GenesPeer-reviewed·Sep 17, 2025
- Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples
Roddy Walsh, Kate Thomson, … Hugh C Watkins·Genetics in MedicinePeer-reviewed·Feb 1, 2017
- Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions
Xiaolei Zhang, Roddy Walsh, … James S. Ware·Genetics in MedicinePeer-reviewed·Oct 12, 2020
- The penetrance of rare variants in cardiomyopathy-associated genes: a cross-sectional approach to estimate penetrance for secondary findings
Kathryn A. McGurk, Xiaolei Zhang, … James S. Ware·The American Journal of Human GeneticsPeer-reviewed·Aug 30, 2023
- A genome-first approach to rare variants in hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank
Joseph Park, Elizabeth Packard, … Daniel James Rader·Human Molecular GeneticsPeer-reviewed·Sep 16, 2021